<sup>177</sup> Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).
Shahneen Sandhu, Shalini Subramaniam, Hayley Thomas, Thean Hsiang Tan, Jeffrey C. Goh, Nattakorn Dhiantravan, Andrew Weickhardt, Anthony M. Joshua, Ian Kirkwood, Sze Ting Lee, Craig Gedye, Andrew Nguyen, David A. Pattison, Ramin Alipour, Roslyn J. Francis, Michael S. Hofman, Andrew Martin, Martin R. Stockler, Ian D. Davis, Louise Emmett (2025). <sup>177</sup> Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5016.
